Are anti-ganglioside antibodies of clinical value in multifocal motor neuropathy?

摘要

Pestronk and colleagues first reported antibodies to GM1 ganglioside in a treatable form of multifocal motor neuropathy (MMN) in 1988. In subsequent years, anti-GM1 and other ganglioside antibodies were reported in a variety of other disorders, including motor neuron disease (MND), Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), monoclonal gammopathy-associated neuropathy, and, occasionally, idiopathic neuropathy, mononeuritis multiplex, radiculopathy, and plexopathy.